Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation of [14C]X842 in Healthy Men
NCT07107672Phase 1Completed
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linaprazan glurate in gastroesophageal reflux disease (GERD), sponsored by Jiangsu Sinorda Biomedicine Co., Ltd. Primary endpoints: Mass balance: the cumulative excretion rate at 22 days, Time to maximum observed concentration at 22 days and 7 more. Started Jun 2022; status: completed.
02
Drugs
linaprazan glurate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT07107672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107672.